Apellis Pharmaceuticals Inc (NASDAQ:APLS) finished Wednesday with a subtraction of -$4.35 to close at $38.83, a downside of -10.06 percent. An average of 3,670,920 shares of common stock have been traded in the last five days. There was a fall of -$9.69 in the past week, and it reached a new high 17 times over the past 12 months. The last 20 days have seen an average of 2,670,200 shares traded, while the 50-day average volume stands at 5,142,322.
APLS stock has decreased by -9.62% in the last month. The company shares reached their 1-month lowest point of $35.06 on 09/27/23. With the stock rallying to its 52-week high on 06/14/23, shares of the company touched a low of $19.83 and a high of $94.75 in 52 weeks. It has reached a new high 22 times so far this year and lost -24.90% or -$12.88 in price. In spite of this, the price is down -59.01% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
APLS stock investors should be aware that Apellis Pharmaceuticals Inc (APLS) stock had its last reported insider trading activity 10 days ago on Sep 18. In this transaction, the insider spent $900,813. Director, Machiels Alec, disposed of 1,250 shares at a price of $45.00 on Sep 18. The insider now owns more than $56,250 worth of shares. Prior to that, Director Machiels Alec went on to Sale 1,250 shares at $45.34 each on Sep 15. An amount of $56,675 was transacted.
Valuation Metrics
Apellis Pharmaceuticals Inc (APLS) stock’s beta is 1.05. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 24.78, the price-to-book (PB) ratio at 13.22.
Financial Health
The quick ratio of Apellis Pharmaceuticals Inc for the three months ended June 29 was 4.52, and the current ratio was 5.11, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.14 and a total debt to equity ratio of 1.29 for the quarter ending June 29. Apellis Pharmaceuticals Inc’s EBITDA margin for the year ending June 29 is -786.41%, while its operating margin for the same period stands at -331.93%. Its gross profit as reported stood at $69.79 million compared to revenue of $75.42 million.
Earnings Surprise
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$122.04 million in the quarter, while revenues of -$177.78 million were shrunk -27.81%. The analyst consensus anticipated Apellis Pharmaceuticals Inc’s latest quarter earnings to come in at -$1.32 per share, but it turned out to be -$1.02, a 22.70% surprise. For the quarter, EBITDA amounted to -$106.88 million. Shareholders own equity worth $117.74 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Apellis Pharmaceuticals Inc (APLS) price momentum. RSI 9-day as of the close on 27 September was 32.81%, suggesting the stock is Neutral, with historical volatility in this time frame at 75.75%.
As of today, APLS’s price is $43.17 -19.98% or -$9.69 from its 5-day moving average. APLS is currently trading -4.46% lower than its 20-day SMA and -53.97% lower than its 100-day SMA. However, the stock’s current price level is -2.91% below the SMA50 and -22.89% below the SMA200.
The stochastic %K and %D were 22.10% and 27.11%, respectively, and the average true range (ATR) was 3.44. With the 14-day stochastic at 22.91% and the average true range at 3.30, the RSI (14) stands at 40.39%. The stock has reached -3.21 on the 9-day MACD Oscillator while the 14-day reading was at -2.25.
Analyst Ratings
Wells Fargo upgraded Apellis Pharmaceuticals Inc (NASDAQ: APLS) to a an Overweight rating in its most recent analyst report. Previously, the stock was rated as an Equal weight. The consensus rating for Apellis Pharmaceuticals Inc (APLS) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell APLS, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 10 others rate it as a “buy”.
What is APLS’s price target for the next 12 months?
Analysts predict a range of price targets between $29.00 and $95.00, with a median target of $64.50. Taking a look at these predictions, the average price target given by analysts for Apellis Pharmaceuticals Inc (APLS) stock is $67.64.
